Keyphrases
Molecular Analysis
100%
EGFR mutation
100%
Pulmonary Adenocarcinoma
100%
ALK-positive
100%
ALK+
100%
ALK-rearranged
100%
Tumor
28%
Epidermal Growth Factor Receptor
28%
Fluorescence in Situ Hybridization
28%
MET Alterations
28%
Non-small Cell Lung Cancer (NSCLC)
14%
Lung Cancer
14%
ErbB2
14%
Lung Carcinogenesis
14%
Crizotinib
14%
Formalin-fixed Paraffin-embedded Tissue
14%
ALK Gene Rearrangement
14%
Mutation Status
14%
KRAS mutation
14%
Putative Drug Targets
14%
Kinase Activity
14%
Janus Kinase 2 (JAK2)
14%
PIK3CA
14%
ALK Inhibitor
14%
Cancer mutations
14%
Gene Sequencing
14%
AKT1
14%
Mutually Exclusive
14%
Genetic Abnormalities
14%
Mutation Screening
14%
Tumor Samples
14%
Screening Panel
14%
Additional mutations
14%
B-Raf
14%
AKT2
14%
MET Amplification
14%
MET Gene
14%
MassARRAY
14%
ALK Kinase
14%
Medicine and Dentistry
Lung Adenocarcinoma
100%
Epidermal Growth Factor Receptor
100%
Fluorescence in Situ Hybridization
40%
Tumor
40%
Lung Cancer
20%
Gene Rearrangement
20%
Phosphotransferase
20%
Neoplasm
20%
Lung Carcinogenesis
20%
Carcinogenesis
20%
Non Small Cell Lung Cancer
20%
Gene Sequence
20%
Crizotinib
20%
ALK Inhibitor
20%
Protein Kinase B Beta
20%
Janus Kinase
20%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Adenocarcinoma
100%
Epidermal Growth Factor Receptor
100%
Non Small Cell Lung Cancer
20%
Lung Cancer
20%
Phosphotransferase
20%
Lung Carcinogenesis
20%
Anaplastic Lymphoma Kinase Inhibitor
20%
Protein Kinase B Beta
20%
Neoplasm
20%
Carcinogenesis
20%
Janus Kinase
20%
Crizotinib
20%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
KRAS
40%
Fluorescence in Situ Hybridization
40%
Carcinogenesis
40%
Genetics
20%
Gene Rearrangement
20%
Gene Sequence
20%
AKT1
20%
Janus Kinase
20%
Phosphotransferase
20%
Kinase
20%
Crizotinib
20%
Protein Kinase B Beta
20%